Table 1.
Baseline demographics
| Olaratumab + Liposomal Doxorubicin (n = 62) | Liposomal Doxorubicin (n = 61) | Total (N = 123) | |
|---|---|---|---|
| Sex, No. (%) | |||
| Female | 62 (100.0) | 61 (100.0) | 123 (100.0) |
| Race, No. (%) | |||
| Asian | 1 (1.6) | 3 (4.9) | 4 (3.3) |
| Black or African American | 5 (8.1) | 1 (1.6) | 6 (4.9) |
| Native Hawaiian or other Pacific Islander | 0 | 1 (1.6) | 1 (0.8) |
| White | 54 (87.1) | 54 (88.5) | 108 (87.8) |
| Other | 2 (3.2) | 2 (3.3) | 4 (3.3) |
| Ethnicity, No. (%) | |||
| Hispanic or Latino | 1 (1.6) | 6 (9.8) | 7 (5.7) |
| Non-Hispanic or Latino | 61 (98.4) | 54 (88.5) | 115 (93.5) |
| Missing | 0 | 1 (1.6) | 1 (0.8) |
| Age, yrs | |||
| Mean (SD) | 58.7 (10.07) | 59.8 (9.70) | 59.3 (9.86) |
| ECOG PS, No. (%) | |||
| 0 | 37 (59.7) | 31 (50.8) | 68 (55.3) |
| 1 | 25 (40.3) | 30 (49.2) | 55 (44.7) |
| Prior chemotherapy, No. (%) | 62 (100.0) | 61 (100.0) | 123 (100.0) |
| Stratification factor (CRF), No. (%) | |||
| Platinum-refractory | 13 (21.0) | 17 (27.9) | 30 (24.4) |
| Platinum-resistant | 49 (79.0) | 44 (72.1) | 93 (75.6) |
| Stratification factor (IVRS), No. (%) | |||
| Platinum-refractory | 15 (24.2) | 16 (26.2) | 31 (25.2) |
| Platinum-resistant | 47 (75.8) | 45 (73.8) | 92 (74.8) |
CRF case report form, ECOG PS Eastern Cooperative Oncology Group performance status, IVRS interactive voice response system, SD standard deviation, yrs. years